Eyevensys S.A.S. is a privately held biotechnology company developing a game changing approach to express therapeutic proteins in situ for the treatment of major ophthalmic diseases.
Eyevensys Unique Approach is based on:• The Electro-Transfection of therapeutic plasmids in the Ciliary muscle
• A Proprietary injection and electro-tranfection device allowing accurate local treatment
• Reliance on Therapeutic Proteins with well-established efficacy records
The ciliary muscle is a ring of smooth muscle in the eye's middle layer (vascular layer) that controls accommodation for viewing objects at varying distances and regulates the flow of aqueous humour. It changes the shape of the lens within the eye. It is a smooth muscle devoid of neuronal cells. The location near the eye surface allows a minimally invasive procedure. It is also at the crossroads between the anterior and posterior segments of the eyes, and protein secretion can be achieved in both eye segments.
Consequently, the ciliary muscle constitutes an ideal transfection target to produce intraocular therapeutic proteins.
Eyevensys S.A.S announced the appointment of Mr. Raffy Kazandjian as CEO
Eyevensys S.A.S. announced the appointment of Mr. Raffy Kazandjian as CEO. Raffy Kazand...
Eyevensys S.A.S. Presents at BioTrinity 2014 - European Biopartnering and Investment Conference
Eyevensys S.A.S. Presents at BioTrinity 2014 - European Biopartnering and Investment Confe...
Eyevensys S.A.S. Presents at BioEquity Europe 2014
Eyevensys S.A.S. Presents at BioEquity Europe 2014, May-21-2014 04:50 PM. Venue: Hilton Am...